Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study.

Arfi A, Baffert S, Soilly AL, Huchon C, Reyal F, Asselain B, Neffati S, Rouzier R, Héquet D.

BMJ Open. 2018 May 18;8(5):e020276. doi: 10.1136/bmjopen-2017-020276.

2.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H.

BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8.

3.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
4.

Can we trust the calculation of texture indices of CT images? A phantom study.

Caramella C, Allorant A, Orlhac F, Bidault F, Asselain B, Ammari S, Jaranowski P, Moussier A, Balleyguier C, Lassau N, Pitre-Champagnat S.

Med Phys. 2018 Apr;45(4):1529-1536. doi: 10.1002/mp.12809. Epub 2018 Mar 13.

PMID:
29443389
5.

[First treatment strategies in the 2 years following lung cancer diagnosis. ESCAP-2011-CPHG, a real-life study carried out in French general hospitals].

Grivaux M, Goupil F, Asselain B, Blanchon F, Collon T, Coëtmeur D, Dayen C, Locher C, Molinier O, Martin F, Debieuvre D.

Rev Mal Respir. 2017 Nov;34(9):991-999. doi: 10.1016/j.rmr.2017.10.001. Epub 2017 Oct 27. French.

PMID:
29111174
6.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2017 Mar 7. pii: S2405-4569(17)30065-2. doi: 10.1016/j.euf.2017.02.017. [Epub ahead of print] Review.

PMID:
28753865
7.

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

Kerbrat P, Desmoulins I, Roca L, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain É, Serin D, Edel M, Debled M, Campone M, Mourret-Reynier MA, Bachelot T, Foucher-Goudier MJ, Asselain B, Lemonnier J, Martin AL, Roché H.

Eur J Cancer. 2017 Jul;79:166-175. doi: 10.1016/j.ejca.2017.03.004. Epub 2017 May 11.

PMID:
28501763
8.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

Dieras V, Pop S, Berger F, Dujaric ME, Beuzeboc P, Escalup L, Bidard FC, Cottu PH, LE Tourneau C, Piperno-Neumann S, Laurence V, Robain M, Asselain B, Pierga JY.

Anticancer Res. 2017 Mar;37(3):1403-1407.

PMID:
28314310
9.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.

PMID:
28279941
10.

Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).

Bennouna J, Phelip JM, André T, Asselain B, Sébastien Koné, Ducreux M.

Clin Colorectal Cancer. 2017 Jun;16(2):129-140.e4. doi: 10.1016/j.clcc.2016.07.013. Epub 2016 Aug 9.

PMID:
28277294
11.

Letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?"

Hill C, Asselain B.

Presse Med. 2017 Mar;46(3):349-352. doi: 10.1016/j.lpm.2017.01.007. Epub 2017 Feb 21. No abstract available.

PMID:
28233706
12.

Study of Intrapatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography.

Lassau N, Coiffier B, Faivre L, Benatsou B, Bidault S, Girard E, Asselain B, Pitre-Champagnat S, Koscielny S.

Invest Radiol. 2017 Mar;52(3):148-154. doi: 10.1097/RLI.0000000000000324.

PMID:
28106614
13.

Risks of second malignancies after breast cancer treatment: Long-term results.

Bazire L, De Rycke Y, Asselain B, Fourquet A, Kirova YM.

Cancer Radiother. 2017 Feb;21(1):10-15. doi: 10.1016/j.canrad.2016.07.101. Epub 2016 Dec 26.

PMID:
28034681
14.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Nov;103(11):951-952. doi: 10.1016/j.bulcan.2016.10.009. Epub 2016 Oct 28. French. No abstract available.

PMID:
28029350
15.

Choroidal melanoma and pregnancy.

Lemaître S, Lévy-Gabriel C, Desjardins L, Plancher C, Asselain B, Vincent-Salomon A, Lumbroso-Le Rouic L, Dendale R, Rouzier R, Delacroix S, Cassoux N.

Acta Ophthalmol. 2016 Nov;94(7):e652-e660. doi: 10.1111/aos.12984. Epub 2016 Mar 24.

16.

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.

Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P.

Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.

PMID:
27592112
17.

[Breast cancer screening: On our way to the future].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Review. French.

PMID:
27473920
18.

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C.

Ann Oncol. 2016 Sep;27(9):1725-32. doi: 10.1093/annonc/mdw260. Epub 2016 Jul 19.

PMID:
27436849
19.

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, Thomas L, Lebbé C, Mortier L, Saiag P, Avril MF, Maubec E, Joly P, Bey P, Cosset JM, Sun JS, Asselain B, Devun F, Marty ME, Dutreix M.

Br J Cancer. 2016 May 24;114(11):1199-205. doi: 10.1038/bjc.2016.120. Epub 2016 May 3.

20.

[One-year survival improvement in lung cancer in France. Results of the prospective real life studies KBP-2000-CPHG and KBP-2010-CPHG].

Grivaux M, Duvert B, Ferrer-Lopez P, Hominal S, Goarant E, Brichet-Martin A, Romand P, Fournier E, Asselain B, Debieuvre D.

Rev Pneumol Clin. 2016 May;72(3):163-70. doi: 10.1016/j.pneumo.2016.02.002. Epub 2016 Apr 22. French.

PMID:
27113617
21.

Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer.

Cabarrou B, Belin L, Somda SM, Falcou MC, Pierga JY, Kirova Y, Delord JP, Asselain B, Filleron T.

Breast Cancer Res Treat. 2016 Apr;156(3):577-585. doi: 10.1007/s10549-016-3789-9. Epub 2016 Apr 13.

PMID:
27075918
22.

[First outpatient satisfaction questionnaire with day-surgery in a French comprehensive cancer center].

Gaujal L, Renou M, Dujaric ME, Baffert S, Tardivon A, Kriegel I, Buecher B, Girod A, Grosset L, Asselain B, Rouzier R, Brédart A, Alran S.

Bull Cancer. 2016 Apr;103(4):330-5. doi: 10.1016/j.bulcan.2016.01.018. Epub 2016 Feb 26. French.

PMID:
26922667
23.

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.

Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, Bidard FC, Rodrigues M, Plancher C, Mariani P, Cassoux N, Decaudin D, Asselain B, Servois V.

Oncologist. 2016 Mar;21(3):281-2. doi: 10.1634/theoncologist.2015-0501. Epub 2016 Feb 24.

24.

Fine Needle Aspiration Biopsy in Uveal Melanoma: Technique, Complications, and Outcomes.

Sellam A, Desjardins L, Barnhill R, Plancher C, Asselain B, Savignoni A, Pierron G, Cassoux N.

Am J Ophthalmol. 2016 Feb;162:28-34.e1. doi: 10.1016/j.ajo.2015.11.005. Epub 2015 Nov 10.

PMID:
26556006
25.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS.

Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13. No abstract available.

PMID:
26467471
26.

Design and statistical principles of the SHIVA trial.

Paoletti X, Asselain B, Kamal M, Servant N, Huppé P, Bieche I, Le Tourneau C.

Chin Clin Oncol. 2015 Sep;4(3):32. doi: 10.3978/j.issn.2304-3865.2015.02.02. Review.

27.

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population.

Rossi L, Stevens D, Pierga JY, Lerebours F, Reyal F, Robain M, Asselain B, Rouzier R.

PLoS One. 2015 Jul 27;10(7):e0132853. doi: 10.1371/journal.pone.0132853. eCollection 2015.

28.

[Work ability in cancer patients: Six years assessment after diagnosis in a cohort of 153 workers].

Sevellec M, Belin L, Bourrillon MF, Lhuilier D, Rérolle E, Le Bideau S, Cotasson-Guillet F, Le Peltier N, Asselain B.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S5-13. doi: 10.1016/S0007-4551(15)31212-1. French.

PMID:
26118877
29.

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.

Baulies S, Belin L, Mallon P, Senechal C, Pierga JY, Cottu P, Sablin MP, Sastre X, Asselain B, Rouzier R, Reyal F.

Br J Cancer. 2015 Jun 30;113(1):30-6. doi: 10.1038/bjc.2015.174. Epub 2015 Jun 16.

30.

Cancer Risk in Women Exposed to Diethylstilbestrol in Utero.

Tournaire M, Devouche E, Espié M, Asselain B, Levadou A, Cabau A, Dunbavand A, Grosclaude P, Epelboin S.

Therapie. 2015 Sep-Oct;70(5):433-41. doi: 10.2515/therapie/2015030. Epub 2015 Jun 12.

PMID:
26071143
31.

Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients.

Piperno-Neumann S, Servois V, Mariani P, Plancher C, Lévy-Gabriel C, Lumbroso-Le Rouic L, Couturier J, Asselain B, Desjardins L, Cassoux N.

J Fr Ophtalmol. 2015 Jun;38(6):526-34. doi: 10.1016/j.jfo.2015.04.005.

32.

The patient-breast cancer care pathway: how could it be optimized?

Baffert S, Hoang HL, Brédart A, Asselain B, Alran S, Berseneff H, Huchon C, Trichot C, Combes A, Alves K, Koskas M, Nguyen T, Roulot A, Rouzier R, Héquet D.

BMC Cancer. 2015 May 12;15:394. doi: 10.1186/s12885-015-1417-4.

33.

Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?

Laé M, Lebel A, Hamel-Viard F, Asselain B, Trassard M, Sastre X, Kirova YM.

Cancer Radiother. 2015 May;19(3):168-74. doi: 10.1016/j.canrad.2015.01.001. Epub 2015 Apr 8.

PMID:
25863565
34.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative.

Ann Oncol. 2015 May;26(5):873-9. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Review. Erratum in: Ann Oncol. 2015 Dec;26(12):2505-6.

PMID:
25725046
35.

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.

de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM.

Clin Cancer Res. 2015 Jun 1;21(11):2530-7. doi: 10.1158/1078-0432.CCR-14-2368. Epub 2015 Feb 27.

36.

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.

Helissey C, Berger F, Cottu P, Diéras V, Mignot L, Servois V, Bouleuc C, Asselain B, Pelissier S, Vaucher I, Pierga JY, Bidard FC.

Cancer Lett. 2015 May 1;360(2):213-8. doi: 10.1016/j.canlet.2015.02.010. Epub 2015 Feb 17.

PMID:
25700777
37.

The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

Montes de Oca R, Gurard-Levin ZA, Berger F, Rehman H, Martel E, Corpet A, de Koning L, Vassias I, Wilson LO, Meseure D, Reyal F, Savignoni A, Asselain B, Sastre-Garau X, Almouzni G.

Mol Oncol. 2015 Mar;9(3):657-74. doi: 10.1016/j.molonc.2014.11.002. Epub 2014 Nov 20.

38.

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D.

PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014.

39.

Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses.

Somda SM, Leconte E, Boher JM, Asselain B, Kramar A, Filleron T.

Stat Methods Med Res. 2016 Dec;25(6):2457-2471. Epub 2014 Feb 24.

PMID:
24567440
40.

[Results of natural hydroxyapatite implants covered with Vicryl® mesh in a series of 704 enucleations].

Ricaud X, Levy-Gabriel C, Lumbroso-Le Rouic L, Cassoux N, Esteve M, Plancher C, Asselain B, Desjardins L.

J Fr Ophtalmol. 2014 Feb;37(2):99-106. doi: 10.1016/j.jfo.2013.05.017. Epub 2013 Nov 7. French.

41.

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma.

Cassoux N, Rodrigues MJ, Plancher C, Asselain B, Levy-Gabriel C, Lumbroso-Le Rouic L, Piperno-Neumann S, Dendale R, Sastre X, Desjardins L, Couturier J.

Br J Ophthalmol. 2014 Jun;98(6):769-74. doi: 10.1136/bjophthalmol-2013-303867. Epub 2013 Oct 29.

42.

Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B.

Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2.

PMID:
24095610
43.

[The adventure of biostatistics in oncology].

Asselain B.

Bull Cancer. 2013 Jul-Aug;100(7-8):647-9. French. No abstract available.

PMID:
24063022
44.

Reasons of not having breast reconstruction: a historical cohort of 1937 breast cancer patients undergoing mastectomy.

Héquet D, Zarca K, Dolbeault S, Couturaud B, Ngô C, Fourchotte V, De La Rochefordière A, Féron JG, Fitoussi A, Bélichard C, Reyal F, Laki F, Hajage D, Sigal B, Asselain B, Alran S; Institut Curie Breast Cancer Group, Roman Rouzier.

Springerplus. 2013 Jul 18;2:325. doi: 10.1186/2193-1801-2-325. eCollection 2013.

45.

The impact of single-nucleotide polymorphisms (SNPs) in OGG1 and XPC on the age at onset of Huntington disease.

Berger F, Vaslin L, Belin L, Asselain B, Forlani S, Humbert S, Durr A, Hall J.

Mutat Res. 2013 Aug 15;755(2):115-9. doi: 10.1016/j.mrgentox.2013.04.020. Epub 2013 Jul 2.

PMID:
23830927
46.

Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study.

Wiazzane N, Chargari C, Plancher C, Tamburini J, Asselain B, Fourquet A, Bouscary D, Kirova YM.

World J Radiol. 2013 Jun 28;5(6):248-52. doi: 10.4329/wjr.v5.i6.248.

47.

Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis.

Zelek L, Laval G, Asselain B.

J Clin Oncol. 2013 Jul 1;31(19):2519-20. doi: 10.1200/JCO.2012.48.4634. Epub 2013 Jun 3. No abstract available.

PMID:
23733778
48.

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.

Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F, Bieche I.

Br J Cancer. 2013 May 14;108(9):1807-9. doi: 10.1038/bjc.2013.164. Epub 2013 Apr 23.

49.

Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies.

Locher C, Debieuvre D, Coëtmeur D, Goupil F, Molinier O, Collon T, Dayen C, Le Treut J, Asselain B, Martin F, Blanchon F, Grivaux M.

Lung Cancer. 2013 Jul;81(1):32-8. doi: 10.1016/j.lungcan.2013.03.001. Epub 2013 Mar 29.

PMID:
23541463
50.

Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.

Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, Fourquet A, Pierga JY, Cottu P, Dieras V, Fourchotte V, Laki F, Alran S, Asselain B, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X.

PLoS One. 2013;8(3):e55901. doi: 10.1371/journal.pone.0055901. Epub 2013 Mar 19.

Supplemental Content

Loading ...
Support Center